CD33 and acute myeloid leukemia: In vitro assays demonstrated that T cells, when exposed to MSCsanti-CD33-anti-CD3, effectively lysed CD33+ AML cells, indicating the immunostimulatory properties of MSCsanti-CD33-anti-CD3 [39].